Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Targeted pharmacological reversal of electrical remodeling after cardioversion

Trial Profile

Targeted pharmacological reversal of electrical remodeling after cardioversion

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Flecainide (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms Flec-SL
  • Most Recent Events

    • 02 Jul 2012 Additional lead trial centres and investigator, actual patient number 760 added as reported by ClinicalTrials.gov.
    • 22 Jun 2012 Results published in the Lancet.
    • 02 May 2011 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top